The present protocol outlines the steps for aligning in vivo visible-light optical coherence tomography fibergraphy (vis-OCTF) images with ex vivo confocal images of the same mouse retina for the purpose of verifying the observed retinal ganglion cell axon bundle morphology in the in vivo images.
In recent years, in vivo retinal imaging, which provides non-invasive, real-time, and longitudinal information about biological systems and processes, has been increasingly applied to obtain an objective assessment of neural damage in eye diseases. Ex vivo confocal imaging of the same retina is often necessary to validate the in vivo findings especially in animal research. In this study, we demonstrated a method for aligning an ex vivo confocal image of the mouse retina with its in vivo images. A new clinical-ready imaging technology called visible light optical coherence tomography fibergraphy (vis-OCTF) was applied to acquire in vivo images of the mouse retina. We then performed the confocal imaging of the same retina as the "gold standard" to validate the in vivo vis-OCTF images. This study not only enables further investigation of the molecular and cellular mechanisms but also establishes a foundation for a sensitive and objective evaluation of neural damage in vivo.
Retinal ganglion cells (RGCs) play a critical role in visual information processing, receiving synaptic inputs through their dendritic trees in the inner plexiform layer (IPL) and transmitting the information via their axons in the retinal nerve fiber layer (RNFL) to the brain1,2,3,4. In diseased conditions such as glaucoma, early RGC degeneration may result in subtle changes in the RNFL, the ganglion cell layer (GCL), the IPL, and the optic nerve in both patients and rodent models5,6,7,8,9. Early detection of these morphological changes in RGCs is thus essential for timely intervention to prevent RGC and vision loss.
We have recently developed a new clinical-ready imaging technology called visible-light optical coherence tomography (vis-OCT) to satisfy the need for in vivo monitoring of RGC damage. Vis-OCT improved the axial resolution, reaching 1.3 µm in the retina10, 11, allowing for the visualization of individual RGC axon bundles in the RNFL. Subsequently, vis-OCT fibergraphy (vis-OCTF) was established to track and quantify RGC damage at the single axon bundle level in mice11,12,13. However, ex vivo confocal imaging of the same retina as the gold standard is often necessary to validate the in vivo findings. Therefore, this study will demonstrate how to align in vivo images acquired by vis-OCTF with ex vivo confocal images of the same mouse retina. The protocol aims to validate the in vivo findings by ex vivo confocal imaging and establish a foundation for examining the molecular and cellular changes underlying RGC damage in diseased conditions.
All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Virginia and conformed to the guideline on Use of Animals from the National Institute of Health (NIH). See the Table of Materials for details related to all materials, reagents, and instruments used in this protocol.
1. In vivo vis-OCT imaging
2. Ex vivo confocal imaging
3. Alignment of in vivo and ex vivo images
The composite vis-OCT fibergram is compared with the corresponding confocal image of flat-mounted retina immunostained with Tuj-1 for RGC axons (Figure 1D, top panel). Axon bundles imaged by vis-OCTF can be matched with the Tu-j1-labeled axon bundles on the confocal image. Blood vessels usually exhibit distinguishable branching structures compared with surrounding axon bundles in fibergram images, which can be matched with the ICAM-2-labeled blood vessels on the confocal image (Figure 1D, bottom panel).
Side-by-side comparison between ex vivo confocal microscopy and in vivo vis-OCT revealed identical RGC axon bundle networks and surrounding retinal vasculature. Note that the confocal image may not match perfectly with the in vivo images, especially in the peripheral region; this is because the retina has been flat-mounted on the slide. Taken together, these results validate the capability of vis-OCT fibergraphy to resolve two adjacent RGC axon bundles with varying sizes in vivo.
Figure 1: Schematic illustration of the alignment of in vivo image with the ex vivo image of the same mouse retina. (A) Schematic of the small-animal vis-OCT system imaging of a mouse eye; (B) Alignment of the four images acquired from the same eye with the optic nerve head placed in the four corners of the field of view; (C) Schematic representation of retina dissection (left), retina flat-mounted with tracked orientation (middle), and retina being imaged by confocal microscopy (right); (D) Comparing vis-OCT fibergraphy and confocal microscopy RGC axon bundle images (top panel), and in vivo En-Face with ex vivo confocal microscopy image of the immunostained for blood vessels (bottom panel). The four images are from the same eye. Yellow scale bars = 100 µm. Numbers (1-11) in panel D each represent blood vessels. Abbreviations: ONH = optic nerve head; vis-OCTF = visible-light optical coherence tomography fibergraphy; RGC = retinal ganglion cell; S = superior; I = inferior; T = temporal; N = nasal. Please click here to view a larger version of this figure.
Supplementary File 1: MATLAB codes for image analysis. Please click here to download this File.
There are two steps in this protocol that require attention. First, it is necessary to ensure that the animal is under deep anesthesia and that their eyes are fully dilated before vis-OCT imaging. If the mice are not adequately anesthetized, their fast breathing may lead to unstable movements of the en face images, which can adversely affect the quality of the fibergram. Moreover, insufficient dilation can also have a negative impact on image quality since the iris may obstruct the light, preventing it from reaching the retina. Second, it is important to mark the left or right eye, as well as the temporal side of the eye, after perfusion but before removing the eyeball from the mouse's eye socket. Since the flat-mounted retina faces upwards with the RNFL on the superficial layer, marking the temporal side will enable proper orientation of the flat-mounted retina.
One of the advantages is that the protocol can be applied to different mouse models of eye diseases, such as retinal ischemia and diabetic retinopathy, as long as the anterior eyes are clear for optical imaging. However, one limitation of this method is that even if the retina is properly fixed for immunostaining and confocal imaging, the axon bundle morphology may change. This occurs due to mis-operations during retina dissection, which may cause ruptures in the axon bundles. Additionally, while retinas are curved bowl-shaped structures when imaged in vivo, they are flattened on slides for confocal imaging. As a result, there may be incomplete overlap between in vivo vis-OCT images and ex vivo confocal images of the peripheral retina.
For troubleshooting: this technique mainly includes two parts. First, for the vis-OCT part, the quality of the mouse eye can greatly impact the success of acquiring clear fibergrams. Therefore, artificial tears were constantly applied to the mouse's eye to keep it moist and bright. The body position of the mouse was also fine-tuned to make the laser shine as perpendicularly onto the retina as possible. These measures together ensured image quality. Second, for the retina dissection part, we found that cutting off the sclera surrounding the retina, rather than ripping it off, was crucial to maintaining the integrity of the ONH structure. When the sclera was ripped off with forceps, the ONH appeared as a fair-sized dark hole under confocal microscopy, with the retina tissue missing from the center. Maintaining a complete ONH structure is essential for in vivo and ex vivo alignments.
In summary, we have established vis-OCTF to directly quantify and track changes at the single axon bundle level in vivo11,12,13. This protocol provides instructions for aligning the in vivo vis-OCTF and ex vivo confocal imaging of the same retinas. These studies lay the foundation for establishing an objective evaluation of neural damage in humans, which can significantly improve glaucoma diagnosis and treatment in the future.
The authors have nothing to disclose.
This study is supported by the Glaucoma Research Foundation Shaffer Grant, 4-CA Cavalier Collaborative Award, R01EY029121, R01EY035088, and Knights Templar Eye Foundation.
Equipment | |||
Halo 100 | Opticent Health, Evanston, IL | ||
Zeiss LSM800 microscope | Carl Zeiss | ||
Drugs and antibodies | |||
4% paraformaldehyde (PFA) | Santz Cruz Biotechnology, SC-281692 | 1-2 drops | |
Bovine serum albumin powder | Fisher Scientific, BP9706-100 | 1:10 | |
Donkey anti Mouse Alexa Fluor 488 dye | Thermo Fisher Scientific, Cat# A-21202 | 1:1,000 | |
Donkey anti rat Alexa Fluor 594 dye | Thermo Fisher Scientific, Cat# A-21209 | 1:1,000 | |
Euthasol (a mixture of pentobarbital sodium (390 mg/mL) and phenytoin sodium (50 mg/mL)) | Covetrus, NDC 11695-4860-1 | 15.6 mg/mL | |
Ketamine | Covetrus, NADA043304 | 114 mg/kg | |
Mouse anti-Tuj1 | A gift from Anthony J. Spano, University of Virginia | 1:200 | |
Normal donkey serum(NDS) | Millipore Sigma, S30-100 mL | 1:100 | |
Phosphate-buffered saline (PBS, 10x), pH 7.4 (Contains 1370 mM NaCl, 27 mM KCl, 80 mM Na2HPO4, and 20 mM KH2PO4) |
Thermo Fisher Scientific, Cat# J62036.K3 | 1:10 | |
Rat anti-ICAM-2 | BD Pharmingen, Cat#553325 | 1:500 | |
Tropicamide drops | Covetrus, NDC17478-102-12 | ||
Triton X-100 (Reagent Grade) |
VWR, CAS: 9002-93-1 | 1:20 | |
Vectashield mounting medium | Vector Laboratories Inc. H2000-10 | ||
Xylazine | Covetrus, NDC59399-110-20 | 17 mg/kg |